Get the Stockscreener App
3.07
4.36%
-0.14
After Hours:
3.22
0.15
+4.89%
Genelux Corp stock is traded at $3.07, with a volume of 55,943.
It is down -4.36% in the last 24 hours and up +21.83% over the past month.
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.
See More
Previous Close:
$3.21
Open:
$3.22
24h Volume:
55,943
Relative Volume:
0.36
Market Cap:
$106.02M
Revenue:
-
Net Income/Loss:
$-28.30M
P/E Ratio:
-4.526
EPS:
-0.6783
Net Cash Flow:
$-21.30M
1W Performance:
+3.72%
1M Performance:
+21.83%
6M Performance:
-19.84%
1Y Performance:
-82.19%
1-Day Range:
$3.0201
$3.22
1-Week Range:
$2.94
$3.50
52-Week Range:
$1.60
$17.48
Genelux Corp Stock (GNLX) Company Profile
Name
Genelux Corp
Sector
Industry
Phone
805-267-9889
Address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Nov-27-23 | Initiated | H.C. Wainwright | Buy |
| Sep-12-23 | Initiated | Maxim Group | Buy |
| Feb-15-23 | Initiated | The Benchmark Company | Speculative Buy |
Genelux Corp Stock (GNLX) Latest News
Individual investors who hold 56% of Genelux Corporation (NASDAQ:GNLX) gained 34%, institutions profited as well - Yahoo Finance
Guggenheim Begins Coverage on Genelux (NASDAQ:GNLX) - Defense World
Guggenheim sees upside in Genelux shares, targets $8 as pivotal cancer trial progresses - Investing.com India
Brokerages Set Genelux Co. (NASDAQ:GNLX) PT at $22.33 - MarketBeat
Highbridge Capital Management LLC Acquires Significant Stake in Genelux Corp - Yahoo Finance
Genelux doses first subject in Phase II trial of NSCLC treatment - Yahoo Finance
Genelux advances NSCLC treatment with Phase 2 Olvi-Vec trial - Investing.com
Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer - Yahoo Finance
Cubist Systematic Strategies LLC Takes $56,000 Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Genelux Co. (NASDAQ:GNLX) Shares Sold by Renaissance Technologies LLC - Defense World
Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit - Yahoo Finance
Genelux announces executive departure By Investing.com - Investing.com Australia
Genelux announces executive departure - Investing.com
Point72 Asia Singapore Pte. Ltd. Acquires Shares of 20,162 Genelux Co. (NASDAQ:GNLX) - Defense World
Affinity Asset Advisors LLC Acquires New Position in Genelux Co. (NASDAQ:GNLX) - Defense World
Highbridge Capital Management LLC Invests $1.23 Million in Genelux Co. (NASDAQ:GNLX) - Defense World
Short Interest in Genelux Co. (NASDAQ:GNLX) Decreases By 7.3% - MarketBeat
Genelux corp insider sells over $170k in company stock - Investing.com India
Genelux director Tyree James L sells shares worth over $4,400 - Investing.com India
Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells $63,134.10 in Stock - MarketBeat
Genelux corp insider sells over $196k in company stock - Investing.com
ROTH MKM analysts initates a Buy rating for Genelux Corp (GNLX) - Knox Daily
Genelux Corp insider sells $89.6k in company stock By Investing.com - Investing.com Australia
Genelux Corp insider sells $89.6k in company stock - Investing.com India
Insider Selling: Genelux Co. (NASDAQ:GNLX) Major Shareholder Sells 42,818 Shares of Stock - MarketBeat
Genelux Corp [NASDAQ: GNLX] Sees Increase in Stock Value - Knox Daily
Genelux Corp (GNLX) Stock: A Year of Decreases and Increases - The InvestChronicle
Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference - Yahoo Finance
Genelux Corp (GNLX) may enjoy gains as insiders got busy in the recent days - Knox Daily
Aladar Szalay Sells 107,045 Shares of Genelux Co. (NASDAQ:GNLX) Stock - Defense World
Genelux Corp insider sells over $550k in company stock - Investing.com India
Analysts Set Genelux Co. (NASDAQ:GNLX) Price Target at $26.75 - MarketBeat
Genelux (NASDAQ:GNLX) Upgraded to Strong-Buy by Roth Capital - Defense World
Genelux Corp [GNLX] Insider Activity: An Update for Investors - Knox Daily
Genelux Co. (NASDAQ:GNLX) Major Shareholder Aladar Szalay Sells 40,000 Shares - Defense World
Genelux (NASDAQ:GNLX) Receives New Coverage from Analysts at Roth Mkm - Defense World
Genelux (NASDAQ:GNLX) Coverage Initiated at Roth Mkm - MarketBeat
Genelux shares gain on Roth/MKM Buy rating, $10 price target - Investing.com
Genelux initiated with a Buy at Roth MKM - TipRanks
Equities Analysts Offer Predictions for Genelux Co.’s Q3 2024 Earnings (NASDAQ:GNLX) - Defense World
Genelux Co. (NASDAQ:GNLX) Sees Large Decrease in Short Interest - MarketBeat
Is Genelux (NASDAQ:GNLX) In A Good Position To Invest In Growth? - Yahoo Finance
Genelux's (GNLX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Genelux Corporation Reports Second Quarter 2024 Financial Results and Provides General Business Updates - StockTitan
Genelux (NASDAQ:GNLX) Trading Down 6.6% - Defense World
Genelux (NASDAQ:GNLX) Stock Price Down 6.6% - MarketBeat
Genelux Corporation (GNLX): A Strong Buy According to Hedge Funds - Yahoo Finance
Genelux stock plunges to 52-week low at $1.69 amid steep annual decline - Investing.com
Genelux Corp Unveils Forward-Looking Corporate Presentation - TipRanks
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024 - GlobeNewswire Inc.
Genelux Corporation to Participate in Fireside Chat at BTIG’s Virtual Biotechnology Conference 2024 - Yahoo Finance
Genelux Corp Stock (GNLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.11%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):